Abstract
Background: Dupilumab is approved in certain patients with atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyposis. We report the effect of dupilumab on AD severity, signs, symptoms, and quality of life (QoL) in adolescents from a randomized, double-blind, placebo-controlled study (LIBERTY AD ADOL; NCT03054428).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
